P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL

• N. Jain,
• G. Roboz,
• M. Konopleva,
• H. Liu,
• G. Schiller,
• E. Jabbour,
• P. Desai,
• D. Whitfield,
• A. Haider,
• O. Zernovak,
• M. Frattini,
• C. Brownstein,
• R. Larson

Affiliations

N. Jain

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

G. Roboz

2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York

M. Konopleva

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

H. Liu

3 Medicine, The University of Chicago, Chicago

G. Schiller

4 Medicine, David Geffen School of Medicine at UCLA, Los Angeles

E. Jabbour

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

P. Desai

2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York

D. Whitfield

5 Cellectis, Inc., New York, United States of America

A. Haider

5 Cellectis, Inc., New York, United States of America

O. Zernovak

5 Cellectis, Inc., New York, United States of America

M. Frattini

5 Cellectis, Inc., New York, United States of America

C. Brownstein

5 Cellectis, Inc., New York, United States of America

R. Larson

3 Medicine, The University of Chicago, Chicago